Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

Leukemia and Lymphoma

Volumn 48, Issue 12, 2007, Pages 2345-2351

  Fenk, Roland ^a   Michael, Mark ^a   Zohren, Fabian ^a   Graef, Thorsten ^b   Czibere, Akos ^a   Bruns, Ingmar ^a   Neumann, Frank ^a   Fenk, Barbara ^a   Haas, Rainer ^a   Kobbe, Guido ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Bendamustine; Bortezomib; Multiple myeloma; Relapsed refractory

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CYTOTOXIC AGENT; DEXAMETHASONE; THALIDOMIDE;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION REACTION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; INFECTION; KIDNEY DYSFUNCTION; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PERIPHERAL PARALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOTHERAPY; REFRACTORY PERIOD; RESPONSE TIME; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; PYRAZINES; SALVAGE THERAPY;

EID: 37149005191     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701694194     Document Type: Article

References (22)

1. Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E. and Hawkins, K. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 348, pp. 1875-1883.
2. Attal, M. and Harousseau, J. L. (1997) Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol Clin North Am, 11, pp. 133-146.
3. Attal, M., Harousseau, J. L., Facon, T., Guilhot, F., Doyen, C. and Fuzibet, J. G. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 349, pp. 2495-2502.
4. Fenk, R., Schneider, P., Kropff, M., Huenerlituerkoglu, A. N., Steidl, U. and Aul, C. (2005) High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study. Br J Haematol, 130, pp. 588-594.
5. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S. and Irwin, D. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348, pp. 2609-2617.
6. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A. and Facon, T. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med, 352, pp. 2487-2498.
7. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S. and Irwin, D. (2005) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 106, pp. 2977-2981.
8. Chang, H., Trieu, Y., Qi, X., Xu, W., Stewart, K. A. and Reece, D. (2007) Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res, 31, pp. 779-782.
9. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J. and Adams, J. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61, pp. 3071-3076.
10. Ma, M. H., Yang, H. H., Parker, K., Manyak, S., Friedman, J. M. and Altamirano, C. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res, 9, pp. 1136-1144.
11. Mitsiades, N., Mitsiades, C. S., Richardson, P. G., Poulaki, V., Tai, Y. T. and Chauhan, D. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood, 101, pp. 2377-2380.
12. Kropff, M. H., Bisping, G., Wenning, D., Volpert, S., Tchinda, J. and Berdel, W. E. (2005) Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res, 29, pp. 587-590.
13. Jagannath, S., Richardson, P. G., Barlogie, B., Berenson, J. R., Singhal, S. and Irwin, D. (2006) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica, 91, pp. 929-934.
14. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D. and Richardson, P. G. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 127, pp. 165-172.
15. Mateos, M. V., Hernandez, J. M., Hernandez, M. T., Gutierrez, N. C., Palomera, L. and Fuertes, M. (2006) Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Results of a multicenter phase 1/2 study. Blood, 108, pp. 2165-2172.
16. Oakervee, H. E., Popat, R., Curry, N., Smith, P., Morris, C. and Drake, M. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol, 129, pp. 755-762.
17. Berenson, J. R., Yang, H. H., Sadler, K., Jarutirasarn, S. G., Vescio, R. A. and Mapes, R. (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol, 24, pp. 937-944.
18. Leoni, L. M., Bailey, B., Reifert, J., Niemeyer, C., Bendall, H. and Dauffenbach, L. (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent posesses a unique mechanism of action. Blood, 102, p. 640.
19. Strumberg, D., Harstrick, A., Doll, K., Hoffmann, B. and Seeber, S. (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs, 7, pp. 415-421.
20. Ponisch, W., Mitrou, P. S., Merkle, K., Herold, M., Assmann, M. and Wilhelm, G. (2006) Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol, 132, pp. 205-212.
21. Knop, S., Straka, C., Haen, M., Schwedes, R., Hebart, H. and Einsele, H. (2005) The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica, 90, pp. 1287-1288.
22. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B. and Gahrton, G. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol, 102, pp. 1115-1123.